ReviewBioMed research international2026
Recurrent Sesquiterpenes in Siparuna guianensis Essential Oil: Therapeutic Potential and Pharmacokinetic Insights.
Review in BioMed research international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Developmental Consequences of Early-Life Exposure and Adulticidal Effects ofMolecules (Basel, Switzerland) · 2026Article
- Recurrent Sesquiterpenes in Siparuna guianensis Essential Oil: Therapeutic Potential and Pharmacokinetic Insights.BioMed research international · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Siparuna guianensis is a neotropical medicinal plant traditionally used for inflammatory and infectious conditions, and its essential oil (EO) has been investigated for diverse biological activities, particularly antimicrobial, antiparasitic, insecticidal, anti-inflammatory, and neuroprotective activities. However, the scientific evidence remains fragmented and predominantly preclinical, with limited integration between chemical recurrence, biological focus, and pharmacokinetic feasibility. This study performed a bibliometric review specifically of the literature on the EO of S. guianensis indexed in the Web of Science Core Collection and integrated it with an in silico pharmacokinetic assessment of recurrent major EO constituents. Bibliometric indicators were analyzed to identify publication trends, research focus, and knowledge gaps. Major compounds reported across studies were compiled, with emphasis on recurrent sesquiterpenes, and key ADME-related parameters, including lipophilicity, aqueous solubility, Caco-2 permeability, and intestinal absorption, were predicted using SwissADME and pkCSM. Eleven eligible articles were included, revealing a limited but thematically consistent research landscape, largely dominated by in vitro investigations conducted in South America. Sesquiterpenes such as germacrene D, bicyclogermacrene, and spathulenol were recurrently identified as major constituents, while β-caryophyllene, α-copaene, α-humulene, α-muurolene, δ-cadinene, iso-shyobunone, and epishyobunone were also reported among the relevant EO components and may represent candidate chemical markers. Taken together, these sesquiterpenes highlight the therapeutic potential of the EO, particularly regarding antimicrobial, antiparasitic, insecticidal, anti-inflammatory, and neuroprotective applications. In silico predictions indicated predominantly lipophilic profiles, low-to-moderate aqueous solubility, high predicted Caco-2 permeability, and elevated intestinal absorption, supporting pharmacokinetic feasibility while highlighting formulation-related limitations. Overall, this work consolidates bibliometric, chemical, and pharmacokinetic evidence specifically related to the EO of S. guianensis and supports its rational interpretation as a source of bioactive volatile constituents, particularly recurrent sesquiterpenes with therapeutic promise, reinforcing the need for experimental pharmacokinetic validation, toxicological assessment, and in vivo efficacy studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.